EUCTR2010-019895-66-IT进行中（未招募）不适用
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer`s Disease. - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 372
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written consent signed by the subject (co-signed by the subject’s next of kin or study partner, if required by the local regulations/guidelines/EC/IRB). 2. Age: 50-80. 3. Males or females of non-childbearing potential (more than two years after the cessation of menses or surgically sterile by means of hysterectomy, bilateral oopherectomy or tubal ligation). Additional blood tests will be done if required by the local regulations/guidelines/EC/IRB for further confirmation of non-childbearing potential. 4. Has a study partner who in the investigator`s judgment is able to provide accurate information as to the subject`s cognitive and functional abilities, who agrees to provide information at clinic visits which require partner input for scale completion, and who signs the necessary consent form if applicable. 5. Fluent in the language of the tests used at the study site. 6. Has had sufficient education or work experience to exclude mental retardation. 7. Willing to complete all aspects of the study (including MRI, lumbar puncture and genotyping) and capable of doing so either alone or with the help of the study partner 8. Not currently being treated with approved marketed medications for AD and the study physician does not anticipate any treatment with one during the study. 9. If not already aware, willing to have their ApoE genotype status withheld until the study is unblinded unless required by the relevant health authority or EC/IRB. If informing the subject of their ApoE status is required, the informed consent may be reviewed and re-signed before treatment begins. 10. Visual and auditory acuity sufficient to perform the cognitive tests (Eye glasses and hearing aids are permitted.) 11. Agree not to donate blood or blood products for transfusion for the duration of the study and for one year after final dose. Et al..
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •CNS Disorders: 1. Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning including but not limited to: head trauma, seizure disorder, neurodegenerative disease, hydrocephalus, cerebral / spinal hematoma, inflammatory disease, CNS infection (e.g. encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder. 2. A history of stroke. 3. A documented history of TIA within the last 12 months. 4. History of schizophrenia, schizoaffective disorder or bipolar disorder 5. Currently meets criteria for major depression. 6. Any other psychiatric condition/disorder which could significantly interfere with the subject’s cooperative participation (e.g., prominent anxiety, agitation or behavioral problems). 7. Current evidence or history of substance abuse disorder (DSM-IV) within 2 years. Imaging related criteria: 8. As assessed by the central reader, MRI evidence of a) more than one lacunar infarct, b) territorial infarct or macroscopic hemorrhage, or c) any deep white matter lesion corresponding to an overall Fazekas score of 3 which requires at least 1 confluent hyperintense lesion on the FLAIR sequence which is 20 mm or greater in any dimension 9. The combined number of microbleeds and areas of leptomeningeal hemosiderosis on MRI is more than 2 on a 1.5T machine or more than 3 on a 3T machine based on the review done by the central reader. 10. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would contraindicate an MRI scan. Cardiovascular Disorders: 11. History of atrial fibrillation except if only one episode which resolved more than three years ago and for which treatment is no longer indicated. 12. Within the last 2 years, unstable or clinically significant cardiovascular disease (e.g. myocardial infarction, angina pectoris, NYHA Class II or more cardiac failure). 13. Any single QTcF above 470 msec, or a difference of more than 30 msec in QTcF between triplicate ECGs at screening; clinically relevant abnormalities on screening ECG based on centralized reading (e.g., QRS equal or longer than 120 msec; multifascicular block; AV block II). 14. Uncontrolled hypertension (i.e. blood pressure generally >160 systolic or >95 mmHg diastolic). Et al...
研究者
相似试验
已完成
3 期
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome (NEPTUNE)Angelman Syndroom10010335NL-OMON49584Ovid Therapeutics Inc.12
进行中（未招募）
1 期
A study investigating new drug PD-0332991 (PALBOCICLIB) for treatment of women with Hormone Receptor-Positive, Her2-Negative Metastatic Breast Cancer. Study has two groups: Allpatients will be treated with Fulvestrant (FASLODEX) and Goserelin (Zoladex). In addition, one group will receive PD-0332991 (PALBOCICLIB), the other group an inactive substance. Neither the patient northe doctor will know the treatment group. The distribution into the groups will be random.HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCERMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000020826EUCTR2013-002580-26-DEPfizer Inc417
已完成
2 期
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with option for an additional two years of treatment10011305Alzheimer's diseasedementiaNL-OMON39809Roche Nederland B.V.48
进行中（未招募）
1 期
A study investigating new drug PD-0332991 (PALBOCICLIB) for treatment of women with Hormone Receptor-Positive, Her2-Negative Metastatic Breast Cancer. Study has two groups: Allpatients will be treated with Fulvestrant (FASLODEX) and Goserelin (Zoladex). In addition, one group will receive PD-0332991 (PALBOCICLIB), the other group an inactive substance. Neither the patient northe doctor will know the treatment group. The distribution into the groups will be random.HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCERMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-002580-26-PTPfizer Inc521
进行中（未招募）
1 期
A Study of Gantenerumab in Patients With Prodromal Alzheimer's DiseaseEUCTR2010-019895-66-SEF. Hoffmann-La Roche Ltd797